SBRT has excellent outcomes for intermediate-risk patients

Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …

Risk for GU side effects higher after SBRT than after IMRT?

A recent, retrospective analysis of Medicare data suggests that men who have first-line stereotactic body radiation therapy (SBRT) are at somewhat higher risk for genitourinary (GU) side effects than men who select intensity-moduated radiation therapy (IMRT). … READ MORE …